MVP expression in the prediction of clinical outcome of locally advanced oral squamous cell carcinoma patients treated with radiotherapy by Luis Henríquez-Hernández et al.
Henríquez-Hernández et al. Radiation Oncology 2012, 7:147
http://www.ro-journal.com/content/7/1/147RESEARCH Open AccessMVP expression in the prediction of clinical
outcome of locally advanced oral squamous cell
carcinoma patients treated with radiotherapy
Luis Alberto Henríquez-Hernández1,2,3*, Mercedes Moreno4, Agustín Rey5, Marta Lloret1,2,3 and Pedro C Lara1,2,3Abstract
Objective: To explore the role of Major Vault Protein (MVP) in oral cavity squamous cell carcinoma patients.
Subjects and Methods: 131 consecutive patients suffering from oral cavity squamous cell carcinoma were
included in the study. In the whole series, the mean follow-up for survivors was 123.11 ± 40.36 months. Patients in
tumour stages I and II were referred to surgery; patients in stage III-IV to postoperative radiotherapy (mean
dose = 62.13 ± 7.74 Gy in 1.8–2 Gy/fraction). MVP expression was studied by immunohistochemistry in paraffin-
embedded tumour tissue.
Results: MVP expression was positive in 112 patients (85.5%) and no relation was found with clinic pathological
variables. MVP overexpression (those tumours with moderate or strong expression of the protein) was related to
insulin-like growth factor receptor-1 (IGF-1R) expression (P = 0.014). Tumour stage of the disease was the most
important prognostic factor related to survival. Tumours overexpressing MVP and IGF-1R were strongly related to
poor disease-free survival (P = 0.008, Exp(B) = 2.730, CI95% (1.302-5.724)) and cause-specific survival (P = 0.014, Exp
(B) = 2.570, CI95% (1.215-5.437)) in patients achieving tumour stages III-IV, in multivariate analysis.
Conclusions: MVP and IGF-1R expression were related in oral squamous cell carcinoma and conferred reduced
long-term survival in patients suffering from advanced stages of the disease.
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Oral carcinoma is commonly treated by surgery or
radiotherapy as local treatments. Although long-term
survival is improving with advances in therapy, out-
comes in locally advanced cases remain suboptimal.
There is a clear need for new prognostic indicators,
which could be used in diagnostics and, consequently, in
the selection of the most effective treatment method.
Vaults are ribonucleoprotein particles with a hollow
barrel-like structure composed of three proteins (the
110 kDa major vault protein (MVP), the two minor
vault poly(ADP-ribose) polymerase (VPARP), and the* Correspondence: lhenriquez@dcc.ulpgc.es
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distribution, and reproduction in any medium240 kDa telomerase-associated protein-1 (TEP1)) and
small untranslated RNA (vRNA) [1]. Vaults have been
classically associated to multidrug resistance [2]. How-
ever, it has been pointed that MVP interacts with several
proteins involved in relevant cellular mechanisms as
PTEN, Erk, or EGF. Furthermore, the expression of MVP
was associated to a malignant phenotype in some cancers,
indicating a direct involvement in tumour development
and progression [3]. MVP has been associated to resist-
ance to radiotherapy [4], probably due to its role in pre-
venting apoptosis by inhibiting the COP-1/p53 axis [5].
Various DNA damaging agents, including ultraviolet ir-
radiation, induce increased MVP transcription and protein
levels [6]. This suggests that vaults may have a role in fa-
cilitating DNA repair processes, which is consistent with
previous work showing that VPARP- and TEP1-deficient
mice have an increased incidence of carcinogen-induced
colon tumours [7]. At the clinical level, the role of MVPioMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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addressed [8]. In that study, MVP was related to poor out-
come after radiotherapy in 78 patients suffering from oro-
pharyngeal carcinoma. The estimated effects of MVP
overexpression appeared somewhat larger in the tongue
cancer patients compared with the tonsil cancer patients
for loco-regional failure and cancer-specific death [8].
However, the underlying mechanisms behind this observa-
tion are not understood and the role of MVP in oral cavity
squamous cell carcinoma has not been deeply studied, es-
pecially in combination with other biological markers.
Insulin-like growth factor-1 receptor (IGF-1R) is a
transmembrane tyrosine kinase receptor commonly
overexpressed in many cancers. Activation of IGF-1R
leads to activation of the ras, raf and MAPK pathways,
resulting in increased proliferation; and of the PI3K
pathway which in turn results in the prevention of apop-
tosis. IGF-1R activation has been associated with
increased radioresistance by increasing cell proliferation
and prevention of apoptosis [9,10]. The expression of
IGF-1R directly influences radioresistance [11]. In that
sense, we have previously reported that IGF-1R overex-
pression is associated with reduced long-term local con-
trol in cervical [12] and oral cancer patients [13]. An
association between MVP and IGF-1R expression has
been reported in cervical patients [14]. Thus, the com-
bined overexpression of MVP and IGF-1R conferred
reduced long-term survival in patients suffering from
cervical cancer who achieved clinical complete response
to radiochemotherapy [14].
The aim of the present study was to assess the expres-
sion of MVP in oral cavity squamous cell carcinoma
patients, its relation with clinical and pathologic prog-
nostic factors and its role in predicting clinical outcome.
In addition, we explored the relation to IGF-1R expres-
sion in this cohort of patients.
Materials and Methods
Patients
The present series of patients was collected from the
tumour registry of the Maxillofacial Surgery Department
of our Institution. All patients were diagnosed and trea-
ted between July 1989 and April 2005. Cases were
excluded from this study if i) they were diagnosed in
other Institution, ii) if pathology blocks were not avail-
able, iii) or if patients received any kind of chemotherapy
either pre or post surgery. Thus, one hundred and thirty
one patients suffering from oral cavity squamous cell
carcinoma (OCSCC) were included in this study.
Patients were diagnosed and treated by surgery and
curative radiation therapy at the Hospital Universitario
de Gran Canaria Dr. Negrín (Las Palmas de Gran
Canaria, Spain). All patients included in the study
received and signed an informed consent. The study wasapproved by the Research Committee of our Institution.
Follow-up was closed in July 2011. The mean follow-up
for survivors (n = 18, 15 males and 3 females) was
123.11 ± 40.36 months (median 113.50, range 72–
204 months). Patients were staged following the TNM
classification and grading according to Broders’ system.
Nineteen patients had stage I disease, 46 stage II, 25
stage III and 41 stage IV. Most patients showed tongue
tumours (64 cases) and grades I (39 cases) and II (74)
carcinomas. Characteristics of patients were summarized
in Table 1.Treatment
All patients were referred to surgery. Additionally, 14
patients were referred to functional cervical dissection,
102 patients were referred to radical cervical dissection
and 1 patient was referred to bilateral cervical dissection.
Fourteen patients did not suffer neck dissection. Those
patients in stages III-IV were referred to postoperative
radiotherapy (RT). Patients in stages I and II were re-
ferred to RT if tumour positive margins were found at
surgery. Thus, 84 patients received postoperative RT up
to a mean dose of 62.13 ± 7.74 Gy (median 65 Gy, range
30–70.20 Gy) in 1.8–2 Gy fractions. No patients were
treated with adjuvant or neoadjuvant chemotherapy.
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MVP expression was studied by immunohistochemistry in
all patients as previously described [14,15]. In short, sec-
tions from paraffin-embedded tissue tumour biopsies were
incubated with mouse anti-MVP monoclonal antibody
(LRP/MVP Ab-2, Clon 1032, Neomarkers, CA) applied at
a 1:100 dilution and incubated for 1 hour at room
temperature in a moist chamber. A secondary biotinylated
antibody (DAKO Detection Kit, LSBA, Carpintería, CA)
and a prepared complex peroxidase–streptavidin biotiny-
lated (DAKO, LSBA, Carpintería, CA) were used after-
wards. Staining was revealed (DAKO, DAB Chromogen,
Carpintería, CA) and counterstained with Harris
hematoxylin. The primary antibody was omitted in one
section as a negative control and a strongly positive
tumour for MVP was used as a positive control.
MVP staining, observed in the cell cytoplasm, was esti-
mated blindly of the clinical patient characteristics and
outcome in zones of maximum expression of the marker
in at least 10 high power fields (400×). MVP expression
was scored semi quantitatively taking into account in-
tensity and area of staining; and classified as low
expressed (negative (−) or slightly (+) positive) or over-
expressed (moderately (++) or strongly (+++) positive)
as previously reported [14] (Figure 1). Data on IGF-1R
expression were obtained from our files [13] followingFigure 1 Representative immunostaining of IGF-1R and MVP
scored semi quantitatively (400x), showing (a, c) low and (b, d)
overexpression, respectively.the same protocol for staining and scoring as previously
described.
Statistical analysis
Outcome after treatment was assessed as Local Disease
Free Survival (LDFS), Regional Disease Free Survival
(RDFS), Distant-Metastasis Free Survival (DMFS),
Disease-Free Survival (DFS), and Cause-Specific Survival
(CSS). Correlations between previously described vari-
ables and outcome during follow-up were analyzed by
the Kaplan–Meier survival test and the differences were
calculated by the log-rank test. Cox regression test was
used for multivariate analysis. Statistical analysis was
performed by SPSS 15.0 software.
Results
MVP and IGF-1R expression was established for all 131
cases. MVP expression was positive in 112 patients
(85.5%) and it was overexpressed in 67 patients (51.1%).
IGF-1R was overexpressed in 60 patients (45.8%). The ex-
pression of both oncoproteins was statistically different
among patients (P= 0.014, Table 2). We observed a posi-
tive association between the expression of MVP and IGF-
1R (Pearson correlation coefficient = 0.224, P = 0.010). We
did not find other statistical associations between other
variables studied.
Actuarial survival ratios after 15 years of follow-up in
the whole series were 65.6, 70.2, 90.6, 49.6, and 57.1%
for LDFS, RDFS, DMFS, DFS, and CSS, respectively.
Tumour grade (I vs. II-III) and stage (I-II vs. III-IV) were
the most important prognostic factors for CSS in multi-
variate analysis (Exp(B) = 3.009, confidence interval [CI]
95% (1.255-7.214), P = 0.014; Exp(B) = 3.085, CI95%
(1.565-6.083), P = 0.001, respectively). MVP and IGF-1R
expression were not differentially expressed according to
tumour location and were not predictive factors in the
whole series (Data not shown).
Because tumour stage was the most important prog-
nostic factor for survival, we analyzed the role of MVP
on long-term control and survival segmenting patients
according to the pathological tumour stage. Twenty out
of the 30 patients (66.7%) suffering tumour stages III-IV
and negative or fairly positive MVP expression wereTable 2 Relation of MVP and IGF-1R expression in oral
tumours
MVP
Low expression Over expression Total
IGF-1R Low expression 42 29 71
Over expression 22 38 60
Total 64 67 131
Expression of oncoproteins was scored semi quantitatively and classified as
low (negative/slightly positive) or overexpressed (moderately/strongly
positive). Chi square test, P = 0.014.
Table 3 Relation of prognostic variables and clinical
outcome in locally advanced oral carcinoma patients
(stages III-IV), n = 66
LDFS RDFS DMFS DFS CSS
Gender P= 0.683 P = 0.744 P = 0.524 P = 0.707 P = 0.485
Age P= 0.882 P = 0.537 P = 0.387 P = 0.574 P = 0.866
Grade P= 0.330 P = 0.053 P = 0.047 P = 0.024 P = 0.008
Surgery margins P= 0.001 P = 0.077 P = 0.388 P = 0.003 P = 0.001
MVP P= 0.214 P = 0.362 P = 0.030 P = 0.020 P = 0.010
IGF-1R P= 0.016 P = 0.153 P = 0.898 P = 0.029 P = 0.009
P values obtained by log rank test.
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tumour stages III-IV and overexpression of MVP were
alive. The results of log rank tests were statistically sig-
nificant for DMFS (P = 0.030) and DFS (P = 0.020)
(Table 3). Moreover, MVP overexpression was a predict-
ive factor for DFS (P = 0.016, Exp(B) = 2.584, CI95%
(1.191-5.604)) and CSS (P = 0.011, Exp(B) = 2.916, CI95%
(1.286-6.629)) in multivariate analysis. MVP expression
was not a predictive factor in patients suffering stage I-II
of the disease. Stratified analyses by tumour grade and
surgery margins did not show any association with MVP
expression (P > 0.05 in all cases).
Combination analysis was performed grouping MVP
and IGF-1R expression in tumours. These analyses
showed that 29 out of the 48 patients (60.4%) suffering
from tumour stages III-IV and negative or fairly positive
MVP/IGF-1R expression were alive, while 3 out of the 18
patients (16.7%) with tumour stages III-IV and overex-
pression of MVP and IGF-1R were alive (P= 0.002). The
results of log rank tests were also statistically significant
for LDFS (P= 0.005) and DFS (P= 0.001) (Figure 2a-c). In
multivariate analysis, MVP and IGF-1R overexpression
was a predictive factor for DFS (P= 0.008, Exp(B) = 2.730,
CI95% (1.302-5.724)) and CSS (P= 0.014, Exp(B) = 2.570,
CI95% (1.215-5.437)).Figure 2 MVP/IGF-1R expression and clinical outcome in oral carcinom
Disease Free Survival, (b) Disease-Free Survival, and (c) Cause-Specific SurviDiscussion
This study was carried out to explore the clinical associ-
ation between MVP expression and prognosis on a series
of OCSCC patients treated by surgery and radiotherapy.
MVP was overexpressed in 67 (51.1%) of our oral cavity
carcinoma patients. Only one study has reported data of
MVP expression in head and neck cancer [8]. Silva et al.
detected positive expression of MVP in 49 out of 78
(62.8%) patients suffering from carcinoma in the poster-
ior third of tongue and the tonsil.
Tumour stage was the most important prognostic fac-
tor for survival in our series. The rates of local recur-
rence for clinical stages III or IV tumours may be as
high as 40%. In our whole series, MVP was not a pre-
dictive factor for survival. Nonetheless, when patients
were segregated according to low (I-II) or high (III-IV)
tumour stage, MVP expression was predictive for DMFS,
DFS, and CSS. The fact that patients with advanced
stages of the disease suffer more amount of adverse
events related to the tumour, together with the radiore-
sistance role of MVP previously reported in tongue and
cervical carcinoma, helps to explain the predictive role
of this oncoprotein only in patients suffering OCSCC in
stage III-IV, all treated with surgery and RT. MVP may
have a role in favouring increased genetic instability by
reducing DNA damage repair by means of non-
homologous end joining (NHEJ) and downregulating
Ku70/80 expression [16]. The most important radiation-
induced DNA damage is the double-strand breaks
(DSB), mainly repaired by NHEJ. Ku70/80 are key genes
in the NHEJ repair pathway for radiation-induced DNA
DSB. If vaults are overexpressed, NHEJ repair may be
suppressed by several mechanisms; thus, genomic in-
stability could arise because either repair of DSB damage
by homologous repair is prevented or NHEJ repair is de-
fective. The PARP-1, part of Vault complex, promotes
homologous repair over NHEJ, suppressing Ku70/80
function. These events are associated with the decisiona patients suffering from tumour stages III-IV (n = 66). (a) Local
va.
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tumour progression and reducing tumour response to
oncologic treatment through the development of resist-
ant cell phenotypes. Our results are in agreement with
the published study of Silva et al. [8] where MVP has
strongly predicted the clinical outcome in 78 oropharyn-
geal cancer patients who received primary radiotherapy
with a curative intent. Because OCSCC in advanced
stages (III-IV) were all referred to postoperative radio-
therapy, the role of MVP was only observed in this sub-
set of patients and not in the whole series.
We reported here the first clinical evidence of a direct
relation between IGF-1R and MVP expression in OCSCC.
The association between both oncoproteins has been pre-
viously reported in cervical carcinoma patients [14]. It
seems that both proteins must be overexpressed to confer
radioresistance and subsequent poor clinical outcome in
cervical cancer. It would be suggested that both MVP and
IGF-1R increase proliferation by activation of Src, PTEN,
ERK and inhibit apoptosis through the ATM COP1/P53
axis, resulting in tumour resistance to DNA damage
agents. It has been reported an association between MVP
expression and cell proliferation, as well as other mole-
cules involved in apoptosis [16]. Thus, resistance to radio-
therapy in the clinical setting as a result of MVP [8,14]
may be causes by the enhanced of proliferation and inhib-
ition of apoptosis, as well as by the regulation of DSB re-
pair by suppressing NHEJ repair through the inhibition of
Ku70/80 [16]. The IGF-1R cooperates with MVP in pre-
venting apoptosis by upregulating BCL-2 and, to a lesser
extent, downregulating BAX [16], and it may also affect
NHEJ repair through the AKT/p38MAPK pathways,
mainly by modifying Ku expression [17]. Activation of
IGF-1R triggers a cascade of reactions involving signal
transduction pathways: Ras, Raf, mitogen-activated pro-
tein kinase and phosphoinositol-3-kinase (PI3K)/AKT/
BAD (Bcl-xL/Bcl2-associated death promoter). IGF-1R
overexpression has been linked to disease progression,
increased resistance to radiotherapy, and poor prognosis
[9,12,18]. IGF-1R gene seems to be a novel downstream
target in an Ataxia Telangiectasia Mutated (ATM)-
mediated DNA damage response pathway. The potential
role of the IGF-1R gene as a target ing an ATM-
dependent pathway, involved in regulating the radiation
response, was recently inferred [19]. Thus, deregulated ex-
pression of the IGF-1R gene after ionizing radiation may
be linked to genomic instability and enhanced transform-
ing capacity [20].
The expression of MVP has a complex regulation not
fully understood, influenced by the expression of other
oncoproteins and other important clinical factors as
hypoxia. In that sense, high MVP expression is related
to severe hypoxia in clinical cervical tumours [21]. Inter-
estingly, hypoxia inhibits the NHEJ DNA repair throughdown-regulating Ku70/80 expression, combined with
increased angiogenesis and altered p53 [22], and an in-
verse association between MVP and KU70/80 exists
[16]. Although the prognosis role of MVP is still contra-
dictory, at a clinical level, vaults have been proposed as a
useful predictive marker associated with radiotherapy re-
sistance [23], and the interaction between IGF-1R and
MVP can help to explain the predictive role of these
oncoproteins in response to radiotherapy [24].
Conclusions
MVP and IGF-1R expression were related in OCSCC
tumours and conferred reduced long-term survival in
patients suffering advanced stages of the disease. The
present results could help to understand the biological
behavior of this tumor type according to the expression
not only of IGF-1R, but also of MVP. In our opinion,
combined MVP/IGF-1R expression could be of rele-
vance in predicting the clinical outcome in this tumour
type. However, new studies including PTEN, P53, BCL-
2, cell proliferation, hypoxia or PI3K markers would be
necessary to precisely define the role of these proteins
on common molecular pathways. These preliminary
results need to be confirmed by a larger clinical trial.
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